Life Sciences IP Management in an Age of Opportunity

By Peter Ackerman, CEO and President, Innovation Asset Group and Russell L Parr, CEO, IPRA Inc.

Intellectual and intangible assets are an especially valuable portion of the asset base in the biotechnology and pharmaceutical sectors. Increased IP interdependence, regulatory information management requirements, and litigation threats make it critical for companies to control their IP assets. The management of IP assets can be best achieved through sound strategy adoption enabled by technologies that help cost-efficiently identify, protect, value and leverage these assets.

Please fill out the following form to access your document.